Latest Period
Q2 2026
Security Snapshot
Candel Therapeutics, Inc. - Common Stock (CADL) Institutional Ownership
CUSIP: 137404109
13F Institutional Holders and Ownership History from Q3 2021 to Q2 2026
Institutions Reporting
137
Shares (Excl. Options)
50,353,452
Price
$10.30
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- CADL on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 50,353,452
- Total 13F value
- $518,701,250
- Portfolio coverage rank
- 0%
- Share change
- +7,165,180
- Value change
- +$87,698,602
- Number of holders
- 137
- Shares outstanding
- 73,256,045
- SEC-reported price per share
- $10.68
- Insider filing price
- $10.68
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- CADL - Candel Therapeutics, Inc. - Common Stock is tracked under CUSIP 137404109.
- 137 institutions reported positions in Q2 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 113 to 137 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $212,897,065 to $518,701,250.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 137 institutions filings for Q2 2026.
Security key
137404109
Latest holder period
Q2 2026
13F holders
137
13D/G owners
6
CIK / CUSIP context first
Open Q2 2026 holders
CADL full holder history
Candel Therapeutics, Inc. SEC filings
Candel Therapeutics, Inc. company facts
Candel Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 137404109:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
CADL
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 8.8% | $31,788,989 | 6,422,018 | RTW Investments, LP | 31 Mar 2026 | |||
| FMR LLC | 15% | +63% | $30,582,610 | +$11,592,390 | 6,318,721 | +61% | FMR LLC | 31 Jan 2025 |
| Manning Paul B | 7.9% | $29,997,375 | 5,790,999 | Paul B Manning | 16 Dec 2024 | |||
| BlackRock, Inc. | 6.6% | +60% | $49,799,460 | +$18,076,891 | 4,834,899 | +57% | BlackRock, Inc. | 30 Jun 2026 |
| ACORN BIOVENTURES, L.P. | 5.2% | $14,115,428 | 2,580,517 | Anders Hove | 25 Jun 2025 | |||
| BAKER BROS. ADVISORS LP | 5% | -26% | $11,882,723 | -$2,550,075 | 2,455,108 | -18% | Baker Bros. Advisors LP | 31 Mar 2025 |
As of 30 Jun 2026, 137 institutional investors reported holding 50,353,452 shares of Candel Therapeutics, Inc. - Common Stock (CADL). This represents 69% of the company’s total 73,256,045 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
64%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 10,990,535 | +0.03% | 0% | $113,202,510 |
| RTW INVESTMENTS, LP | 8.8% | 6,422,018 | 0% | 0.56% | $66,146,785 |
| BlackRock, Inc. | 6.8% | 4,969,040 | +60% | 0% | $51,181,112 |
| STATE STREET CORP | 4.8% | 3,549,823 | +334% | 0% | $36,563,177 |
| ACORN CAPITAL ADVISORS, LLC | 4.8% | 3,497,948 | 0% | 9.8% | $36,028,864 |
| Portolan Capital Management, LLC | 4.8% | 3,490,398 | +21% | 1.3% | $35,951,099 |
| Saturn V Capital Management LP | 4.5% | 3,303,686 | +14% | 4.9% | $34,027,966 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.7% | 2,694,040 | +9.4% | 0% | $27,748,612 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.1% | 1,571,021 | +52% | 0% | $16,183,884 |
| MILLENNIUM MANAGEMENT LLC | 1.5% | 1,093,905 | +3.2% | 0.01% | $11,267,222 |
| Halter Ferguson Financial Inc. | 1.1% | 772,461 | -15% | 1.3% | $7,956,345 |
| NORTHERN TRUST CORP | 0.67% | 492,465 | +52% | 0% | $5,072,389 |
| KENNEDY CAPITAL MANAGEMENT LLC | 0.67% | 488,291 | +427% | 0.09% | $5,029,397 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.6% | 437,150 | +63% | 0% | $4,502,645 |
| VANGUARD FIDUCIARY TRUST CO | 0.56% | 412,109 | +47% | 0% | $4,244,723 |
| Sands Capital Alternatives, LLC | 0.55% | 405,837 | 0% | 0.68% | $4,180,121 |
| GOLDMAN SACHS GROUP INC | 0.42% | 305,216 | +34% | 0% | $3,143,724 |
| MARSHALL WACE, LLP | 0.41% | 300,641 | 0% | $3,096,603 | |
| BANK OF AMERICA CORP /DE/ | 0.38% | 278,944 | +488% | 0% | $2,873,123 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.31% | 227,939 | +102% | 0% | $2,347,772 |
| WELLINGTON MANAGEMENT GROUP LLP | 0.28% | 205,745 | 0% | $2,119,174 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.27% | 199,454 | +79% | 0% | $2,054,376 |
| Tanager Wealth Management LLP | 0.27% | 198,175 | 0% | 0.18% | $2,041,203 |
| Bank of New York Mellon Corp | 0.26% | 191,701 | +41% | 0% | $1,974,516 |
| UBS Group AG | 0.23% | 169,271 | +13% | 0% | $1,743,491 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
20
Latest
Q2 2026
Rows shown
1-20 of 20
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 50,353,452 | $518,701,250 | +$87,698,602 | $10.30 | 137 |
| 2026 Q1 | 43,425,726 | $212,897,065 | +$93,310,969 | $4.90 | 113 |
| 2025 Q4 | 23,634,025 | $133,509,415 | +$5,752,184 | $5.65 | 84 |
| 2025 Q3 | 22,668,478 | $115,621,483 | -$1,871,335 | $5.10 | 81 |
| 2025 Q2 | 23,037,394 | $116,569,933 | +$8,831,720 | $5.06 | 78 |
| 2025 Q1 | 21,190,126 | $119,726,836 | +$12,537,033 | $5.65 | 82 |
| 2024 Q4 | 17,950,985 | $155,743,026 | +$97,379,454 | $8.68 | 70 |
| 2024 Q3 | 6,693,196 | $46,384,699 | +$3,074,083 | $6.93 | 51 |
| 2024 Q2 | 5,961,761 | $36,964,279 | +$13,959,987 | $6.20 | 45 |
| 2024 Q1 | 3,780,257 | $5,972,529 | -$231,572 | $1.58 | 18 |
| 2023 Q4 | 4,027,160 | $5,919,504 | -$1,196,574 | $1.47 | 21 |
| 2023 Q3 | 5,257,852 | $4,856,205 | -$147,500 | $0.92 | 19 |
| 2023 Q2 | 5,370,044 | $6,766,125 | -$142,743 | $1.26 | 19 |
| 2023 Q1 | 5,478,268 | $7,437,200 | +$69,459 | $1.35 | 20 |
| 2022 Q4 | 5,420,630 | $9,702,154 | -$1,788,500 | $1.79 | 20 |
| 2022 Q3 | 6,080,809 | $19,096,287 | -$834,398 | $3.14 | 22 |
| 2022 Q2 | 6,345,954 | $20,561,000 | -$1,159,878 | $3.24 | 21 |
| 2022 Q1 | 6,674,026 | $33,969,000 | -$1,719,786 | $5.08 | 21 |
| 2021 Q4 | 6,951,728 | $54,359,000 | +$875,765 | $7.82 | 20 |
| 2021 Q3 | 4,884,284 | $52,945,000 | +$44,146,000 | $10.84 | 12 |